ExodusPoint Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

ExodusPoint Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-242,457	Closed	-$3.79M	–	1450
2025 Q1	$3.79M	Buy	+242,457	New	+$3.42M	0.04%	505
2024 Q4	–	Sell	-323,701	Closed	-$3.01M	–	1500
2024 Q3	$3.01M	Sell	323,701 -789,881	-71%	-$7.79M	0.02%	585
2024 Q2	$10.4M	Buy	1,113,582 +891,360	+401%	+$8.06M	0.07%	246
2024 Q1	$2.2M	Buy	+222,222	New	+$1.66M	0.02%	664
2023 Q4	–	Sell	-33,545	Closed	-$178K	–	1447
2023 Q3	$178K	Buy	+33,545	New	+$285K	﹤0.01%	1539
2023 Q1	–	Sell	-65,995	Closed	-$977K	–	1734
2022 Q4	$977K	Buy	65,995 +18,940	+40%	+$331K	0.01%	955
2022 Q3	$899K	Buy	+47,055	New	+$1.07M	0.01%	1153

Other funds holding ARQT

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

ExodusPoint Capital Management's ARQT Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 242,457 shares — an estimated $3.79M sold.

ExodusPoint Capital Management first reported a position in ARQT in Q3 2022 and held it in 7 quarters. The position peaked at $10.4M in Q2 2024. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

ExodusPoint Capital Management reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 242,457 Arcutis Biotherapeutics shares in Q2 2025, an estimated $3.79M.
ExodusPoint Capital Management first reported a position in Arcutis Biotherapeutics in Q3 2022 and held it in 7 quarters.
ExodusPoint Capital Management's Arcutis Biotherapeutics position peaked at $10.4M in Q2 2024.
230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.